Skip to content
Search:
Search
Facebook page opens in new window
 
ADCS
Alzheimer's Disease Cooperative Study
ADCSADCS
  • About Us
    • About ADCS
    • Meet the Directors
    • ADCS Cores
    • ADCS Clinical Trials Network
    • ADCS Intervention Selection Committee
    • Steering Committee Voting Members
  • Public & Participant Resources
    • About Alzheimer’s Disease
    • AD Resources
    • Clinical Sites
    • Types of Studies
    • Clinical Trials
    • Lifestyle Interventions
    • Alzheimer’s Study Quilt Project
  • Investigator Resources
    • Publications
    • Study Resources
    • Data Sharing
    • Biorepository
    • ADCS Instruments
    • Preliminary Proposals
    • Combination Therapy Call OPEN
  • CTMS
    • Clinical Conductor Enterprise
    • Clinical Conductor Site Portals
      • Donate
  • Steering Committee Members
  • Staff Resources
  • DONATE
  • About Us
    • About ADCS
    • Meet the Directors
    • ADCS Cores
    • ADCS Clinical Trials Network
    • ADCS Intervention Selection Committee
    • Steering Committee Voting Members
  • Public & Participant Resources
    • About Alzheimer’s Disease
    • AD Resources
    • Clinical Sites
    • Types of Studies
    • Clinical Trials
    • Lifestyle Interventions
    • Alzheimer’s Study Quilt Project
  • Investigator Resources
    • Publications
    • Study Resources
    • Data Sharing
    • Biorepository
    • ADCS Instruments
    • Preliminary Proposals
    • Combination Therapy Call OPEN
  • CTMS
    • Clinical Conductor Enterprise
    • Clinical Conductor Site Portals
      • Donate
  • Steering Committee Members
  • Staff Resources
  • DONATE

NPR interviewed Dr. Reisa Sperling about the upcoming A4 trial and why it is unprecedented in the field of Alzheimer’s clinical research.

You are here:
  1. Home
  2. Research News
  3. NPR interviewed Dr. Reisa Sperling…

One of the longest and most anticipated Alzheimer drug studies in history is about to begin, and Dr. Reisa Sperling is wondering if people will come. It’s called the A4 study, and Sperling is the project leader.

Post navigation

PreviousPrevious post:The good news on Alzheimer’s: Better ways to diagnose it. Drug trials offer promise.NextNext post:In the largest-ever genetic analysis conducted on Alzheimer’s disease, an international group of researchers has identified 11 new genes associated with the disorder, doubling the number of known gene variants linked to it.
ADCS Research News
  • Home Based Assessments Trial Primary Paper in the Journal of Alzheimer’s & Dementia
  • “Young Latino’s Working in Alzheimer’s” Airs Tonight on UCSD TV and is Streaming on the Brain Channel
  • 40 Sites Across The Country To Test New Alzheimer’s Drug
  • Newly discovered Alzheimer’s genes lead to hope for future treatments
  • ADCS Director Howard Feldman, MD talks about the T2 Protect trial and a bright future for Alzheimer’s research
About ADCS
The Alzheimer’s Disease Cooperative Study (ADCS) was formed in 1991 as a cooperative agreement between the National Institute on Aging (NIA) and the University of California San Diego.
Contact Us
  • E-mail:
    alzinfo@ucsd.edu
  • Phone:
    858-246-1333

Find us on:

Facebook page opens in new windowRss page opens in new windowMail page opens in new window
Location
Shipping Address:
9452 Medical Center Drive
4th Floor
La Jolla, CA 92037

Mailing Address:
9500 Gilman Dr
MC0949
La Jolla, CA 92093-0949
Copyright 2017 Regents of the University of California.
Go to Top